Profile data is unavailable for this security.
About the company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
- Revenue in USD (TTM)411.01k
- Net income in USD-4.85m
- Incorporated2004
- Employees5.00
- LocationLexaria Bioscience Corp100 - 740 MCCURDY ROADKELOWNA V1X 2P7CanadaCAN
- Phone+1 (250) 765-6424
- Fax+1 (604) 685-7602
- Websitehttps://www.lexariabioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc | 16.45m | -14.11m | 34.84m | 14.00 | -- | 0.8503 | -- | 2.12 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Eyenovia Inc | 31.41k | -37.28m | 38.49m | 57.00 | -- | -- | -- | 1,225.34 | -0.7897 | -0.7897 | 0.0007 | -0.0425 | 0.0013 | -- | 0.0418 | 551.05 | -154.24 | -80.31 | -262.28 | -117.70 | -1,489.11 | -- | -118,693.60 | -680.95 | 0.267 | -40.92 | 1.20 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 39.87m | 317.00 | -- | 0.4741 | 29.71 | 0.3317 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Fortress Biotech Inc | 82.62m | -49.54m | 43.80m | 186.00 | -- | 2.43 | -- | 0.5302 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Aadi Bioscience Inc | 23.82m | -65.44m | 46.03m | 70.00 | -- | 0.5842 | -- | 1.93 | -2.43 | -2.43 | 0.8829 | 3.20 | 0.1884 | 0.6393 | 4.96 | 267,606.80 | -51.76 | -50.25 | -60.12 | -56.15 | 87.18 | -- | -274.77 | -473.97 | 3.92 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 48.86m | 14.00 | -- | 2.04 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 50.02m | 137.00 | -- | 1,844.41 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 50.91m | 5.00 | -- | 5.03 | -- | 123.86 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Earth Science Tech Inc | 20.30m | 1.98m | 55.41m | 32.00 | 28.06 | 17.50 | 25.84 | 2.73 | 0.0064 | 0.0064 | 0.0658 | 0.0103 | 5.40 | 36.44 | -- | 634,456.90 | 52.57 | -37.98 | 77.89 | -- | 69.40 | 63.87 | 9.74 | -15.48 | 1.24 | 3.57 | 0.0261 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 55.58m | 134.00 | 4.70 | 0.2224 | 1.70 | 0.2158 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Qilian International Holding Group Ltd | 29.87m | -7.86m | 57.81m | 298.00 | -- | 1.32 | -- | 1.94 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| SCYNEXIS Inc | 9.67m | -35.39m | 59.43m | 29.00 | -- | 0.9839 | -- | 6.15 | -0.735 | -0.735 | 0.2005 | 1.60 | 0.0736 | -- | 0.7011 | 333,344.80 | -26.95 | -30.02 | -31.99 | -36.35 | -55.82 | -- | -366.09 | -86.76 | -- | -- | 0.1747 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 66.76m | 25.00 | 20.57 | 5.51 | 19.92 | 5.42 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| CEL-SCI Corp | 0.00 | -29.10m | 68.87m | 43.00 | -- | 7.17 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Data as of Sep 19 2024. Currency figures normalised to Lexaria Bioscience Corp's reporting currency: US Dollar USD
12.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 1.02m | 6.45% |
| Invenomic Capital Management LPas of 30 Jun 2024 | 513.57k | 3.25% |
| Geode Capital Management LLCas of 30 Jun 2024 | 114.78k | 0.73% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 93.59k | 0.59% |
| Waystone Fund Management (IE) Ltd.as of 31 Dec 2023 | 61.35k | 0.39% |
| GenTrust LLCas of 30 Jun 2024 | 60.00k | 0.38% |
| Raymond James Financial Services Advisors, Inc.as of 30 Jun 2024 | 48.80k | 0.31% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 39.30k | 0.25% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 27.45k | 0.17% |
| The Welch Group LLCas of 30 Jun 2024 | 24.00k | 0.15% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
